Banque Cantonale Vaudoise Has $5.35 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Banque Cantonale Vaudoise increased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 46.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,111 shares of the medical research company's stock after purchasing an additional 25,886 shares during the period. Banque Cantonale Vaudoise's holdings in Edwards Lifesciences were worth $5,353,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. W.G. Shaheen & Associates DBA Whitney & Co bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $7,290,000. Quest Partners LLC bought a new stake in Edwards Lifesciences in the third quarter valued at approximately $406,000. Swiss National Bank lifted its position in shares of Edwards Lifesciences by 0.5% in the third quarter. Swiss National Bank now owns 1,788,600 shares of the medical research company's stock valued at $118,030,000 after buying an additional 8,300 shares during the last quarter. S&CO Inc. lifted its holdings in Edwards Lifesciences by 24.5% during the 3rd quarter. S&CO Inc. now owns 61,555 shares of the medical research company's stock valued at $4,062,000 after purchasing an additional 12,120 shares during the last quarter. Finally, RiverPark Advisors LLC increased its holdings in shares of Edwards Lifesciences by 58.1% in the third quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company's stock valued at $1,362,000 after purchasing an additional 7,583 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

EW traded up $0.31 on Tuesday, reaching $70.20. The stock had a trading volume of 4,914,609 shares, compared to its average volume of 4,655,065. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $41.40 billion, a price-to-earnings ratio of 9.88, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a 50-day moving average of $67.53 and a 200-day moving average of $76.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the business earned $0.59 EPS. The firm's quarterly revenue was up 8.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Barclays lowered their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a report on Monday, September 9th. Jefferies Financial Group cut Edwards Lifesciences from a "buy" rating to a "hold" rating and dropped their price target for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Truist Financial decreased their price objective on Edwards Lifesciences from $71.00 to $70.00 and set a "hold" rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group reduced their target price on shares of Edwards Lifesciences from $66.00 to $63.00 and set a "hold" rating for the company in a research report on Friday, October 25th. Finally, Wells Fargo & Company lowered their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.